Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis.
14–3-3η(eta)
Biomarker
CCP antibody
Juvenile idiopathic arthritis
Rheumatoid factor
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
received:
06
05
2020
accepted:
04
02
2021
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA. JIA patients (n = 151) followed by the Pediatric Rheumatology Core at Children's Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 19), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels > 0.2 ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71). Elevated 14-3-3η levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis. Serum 14-3-3η can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3η does not appear to correlate with disease activity in JIA.
Sections du résumé
BACKGROUND
BACKGROUND
Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA.
METHODS
METHODS
JIA patients (n = 151) followed by the Pediatric Rheumatology Core at Children's Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 19), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels > 0.2 ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71).
RESULTS
RESULTS
Elevated 14-3-3η levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis.
CONCLUSION
CONCLUSIONS
Serum 14-3-3η can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3η does not appear to correlate with disease activity in JIA.
Identifiants
pubmed: 33593401
doi: 10.1186/s12969-021-00502-8
pii: 10.1186/s12969-021-00502-8
pmc: PMC7885348
doi:
Substances chimiques
14-3-3 Proteins
0
Autoantibodies
0
Biomarkers
0
Peptides, Cyclic
0
cyclic citrullinated peptide
0
Rheumatoid Factor
9009-79-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Références
Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-35-9
pubmed: 25365087
Arthritis Rheum. 1994 Dec;37(12):1761-9
pubmed: 7986222
J Rheumatol. 2013 May;40(5):715-24
pubmed: 23418376
Pediatr Rheumatol Online J. 2013 Aug 29;11(1):31
pubmed: 23987731
Clin Chem Lab Med. 2009;47(12):1525-30
pubmed: 19842993
Electron Physician. 2016 Sep 20;8(9):2897-2903
pubmed: 27790341
Arthritis Res Ther. 2016 Apr 01;18:76
pubmed: 27037016
Joint Bone Spine. 2013 Jan;80(1):38-43
pubmed: 22575064
J Rheumatol. 2014 Nov;41(11):2104-13
pubmed: 25128504
J Rheumatol. 2015 Sep;42(9):1587-94
pubmed: 26178283
Rheumatology (Oxford). 2009 Aug;48(8):972-7
pubmed: 19535609
J Rheumatol. 2015 Oct;42(10):1995
pubmed: 26429210
Arthritis Rheum. 2009 May 15;61(5):658-66
pubmed: 19405003
Arthritis Res Ther. 2016 Feb 01;18:37
pubmed: 26832367
Arthritis Res Ther. 2014 Apr 21;16(2):R99
pubmed: 24751211
Pediatr Rheumatol Online J. 2012 Aug 29;10(1):29
pubmed: 22931121
J Rheumatol. 2016 Apr;43(4):799-803
pubmed: 26879356
Clin Epidemiol. 2014 Oct 24;6:379-93
pubmed: 25368531
Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82
pubmed: 21452260
Arthritis Res Ther. 2015 Oct 09;17:280
pubmed: 26449724
Immunol Invest. 2008;37(8):849-57
pubmed: 18991100
J Rheumatol. 2004 Sep;31(9):1829-33
pubmed: 15338508
Indian J Pediatr. 2010 Jan;77(1):41-4
pubmed: 20135267